Clinical Trial Update: PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study evaluated safety, tolerability, and plasma pharmacokinetics of escalating single and repeated oral doses of TMC558445, alone and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-1

Drugs mentioned

• Darunavir (darunavir)
• TMC310911
• TMC558445

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV-1 | Phase 1 | Status: COMPLETED